伴侶動物術後疼痛管理治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Companion Animal Postoperative Pain Management Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月08日 | 出版商:

Global Market Insights Inc. | 英文 229 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，全球伴侶動物術後疼痛管理治療市場價值為1.335億美元，預計在預測期內複合年成長率為6.5%。伴侶動物外科手術頻率的增加推動了市場的擴張。隨著寵物數量的激增和獸醫護理的發展，對高效的術後疼痛管理解決方案的需求不斷增加。例如，美國寵物產品協會 (APPA) 報告稱，美國寵物擁有量已飆升至 8,500 萬隻，每年都有許多寵物接受手術。外科手術的增加強調了有效疼痛管理的迫切需要，強調了治療在促進動物福利和復原方面的作用。

整個伴侶動物術後疼痛管理治療產業根據藥物類別、給藥途徑、適應症、動物類型、配銷通路和地區進行分類。

伴侶動物術後疼痛管理治療市場依藥物類別分為非類固醇抗發炎藥、鴉片類藥物、麻醉劑、α2 激動劑和其他類別。 2023年，非類固醇抗發炎藥領域以1.037億美元的估值引領市場。非類固醇類抗發炎藥物 (NSAID) 因其在減輕寵物疼痛和發炎方面的功效和安全性得到證實而引領市場。它們在獸醫處方中佔有很大佔有率，凸顯了它們的突出地位，強調了它們在術後護理中的關鍵作用。 NSAIDs 在臨床應用中建立的聲譽，加上藥物配方的不斷創新，鞏固了其領先的市場地位。

根據給藥途徑，市場分為口服、腸胃外和外用部分。 2023年，口腔細分市場以57.1%的主導佔有率佔據市場主導地位。口腔部分的突出之處在於其方便、直接給藥和有效緩解疼痛。獸醫和寵物主人青睞口服療法（無論是片劑、膠囊或口服混懸液）來控制術後疼痛，因為它們比注射或外用藥更容易給藥。該領域的主導地位得益於獸醫實踐中疼痛管理意識的提高以及口服藥物配方的創新，以提高功效和安全性。

2023年，美國在北美伴侶動物術後疼痛管理治療市場中處於領先地位，銷售額達5,920萬美元，預計未來幾年將出現良好的成長。北美的領先地位歸功於其先進的獸醫基礎設施、高寵物擁有率以及強勁的研發投資。該地區強大的醫療保健框架和尖端疼痛管理解決方案的迅速採用擴大了其市場佔有率。人們對改善寵物生活品質的日益關注，以及寵物主人對有效疼痛管理的認知不斷提高，刺激了對先進治療方法的需求。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

Assisi Animal Health
Bayer AG
Bimeda Animal Health
Boehringer Ingelheim International GmbH
Ceva Sante Animale
Chanelle Pharma Group
Dechra Pharmaceuticals
Elanco Animal Health Incorporated
Merck Animal Health
Norbrook
SAVA Vet
Vetoquinol S.A.
Virbac Group
Zoetis Inc.

簡介目錄

Product Code: 10730

The Global Companion Animal Postoperative Pain Management Therapeutics Market was valued at USD 133.5 million in 2023 and is projected to grow at a CAGR of 6.5% during the forecast period. The market's expansion is driven by the rising frequency of surgical procedures in companion animals. As pet ownership surges and veterinary care evolves, there's an escalating need for efficient post-surgery pain management solutions. For example, the American Pet Products Association (APPA) reports that pet ownership in the U.S. has soared to 85 million, with many pets undergoing surgeries each year. This increase in surgical procedures underscores the critical need for effective pain management, emphasizing the role of therapeutics in promoting animal welfare and recovery.

The overall companion animal postoperative pain management therapeutics industry is classified based on the drug class, route of administration, indication, animal type, distribution channel, and region.

The market for companion animal postoperative pain management therapeutics is segmented by drug class into NSAIDs, opioids, anesthetics, alpha-2 agonists, and other categories. In 2023, the NSAIDs segment led the market with a valuation of USD 103.7 million. Nonsteroidal anti-inflammatory drugs (NSAIDs) lead the market due to their proven efficacy and safety in alleviating pain and inflammation in pets. Their prominence is underscored by their substantial share in veterinary prescriptions, emphasizing their pivotal role in postoperative care. NSAIDs' established reputation in clinical applications, paired with continuous innovations in drug formulations, solidifies their leading market position.

The market is divided into oral, parenteral, and topical segments based on the route of administration. In 2023, the oral segment commanded the market with a dominant share of 57.1%. The oral segment's prominence stems from its convenience, straightforward administration, and effective pain alleviation. Veterinarians and pet owners favor oral therapeutics-be it tablets, capsules, or oral suspensions-for postoperative pain management due to their ease of administration over injectables or topicals. The segment's dominance is bolstered by heightened awareness of pain management in veterinary practices and innovations in oral drug formulations that enhance efficacy and safety.

In 2023, the U.S. led the North American market for companion animal postoperative pain management therapeutics, accounting for USD 59.2 million, with promising growth anticipated in the coming years. North America's leadership is attributed to its advanced veterinary infrastructure, high rates of pet ownership, and robust investments in R&D. The region's strong healthcare framework and the swift adoption of cutting-edge pain management solutions amplify its market share. An intensified focus on improving pets' quality of life, alongside rising awareness among pet owners about effective pain management, fuels the demand for advanced therapeutics.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising awareness of animal welfare
  - 3.2.1.2 Increasing pet ownership
  - 3.2.1.3 Development of novel therapeutics
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Adverse effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 NSAIDs
5.3 Anesthetics
5.4 Opioids
5.5 Alpha-2 agonists
5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Parenteral
6.4 Topical

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Dogs
7.3 Cats
7.4 Other animal types

Chapter 8 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Orthopedic surgery
8.3 Soft tissue surgery
8.4 Dental surgery
8.5 Oncologic surgery
8.6 Other surgeries

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Veterinary hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 Saudi Arabia
- 10.6.2 South Africa
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa